Induction of protective immunity against MHC class I-deficient, HPV16-associated tumours with peptide and dendritic cell-based vaccines

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68378050%3A_____%2F10%3A00346747" target="_blank" >RIV/68378050:_____/10:00346747 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Induction of protective immunity against MHC class I-deficient, HPV16-associated tumours with peptide and dendritic cell-based vaccines

Popis výsledku v původním jazyce

We investigated the efficacy of peptide and peptide-pulsed dendritic cell-based vaccines in a murine model of experimental MHC class I-deficient tumours (TC-1/A9), expressing E6/E7 oncogenes derived from HPV16. Peptide vaccine based on the ?short peptideE749-57 harbouring the CTL epitope and co-administered to the C57BL/6 mice with CpG oligodeoxynucleotide as adjuvant effective against MHC class I-positive but not ?deficient tumours, while the ?longer peptide E744-62 (harbouring CTL and Th epitopes)-based vaccines were effective against MHC class I-deficient tumours. Further, we investigated the efficacy of dendritic cells pulsed with either E749-57 or E744-62 peptides. Treatment with dendritic cells pulsed with a ?short peptide resulted in the tumourgrowth inhibition, albeit weaker as compared to the immunisation with the longer peptide-containing DC. Our data demonstrate that cell-based vaccines can be designed to elicit immunity against MHC class I-deficient tumours.

Název v anglickém jazyce

Induction of protective immunity against MHC class I-deficient, HPV16-associated tumours with peptide and dendritic cell-based vaccines

Popis výsledku anglicky

We investigated the efficacy of peptide and peptide-pulsed dendritic cell-based vaccines in a murine model of experimental MHC class I-deficient tumours (TC-1/A9), expressing E6/E7 oncogenes derived from HPV16. Peptide vaccine based on the ?short peptideE749-57 harbouring the CTL epitope and co-administered to the C57BL/6 mice with CpG oligodeoxynucleotide as adjuvant effective against MHC class I-positive but not ?deficient tumours, while the ?longer peptide E744-62 (harbouring CTL and Th epitopes)-based vaccines were effective against MHC class I-deficient tumours. Further, we investigated the efficacy of dendritic cells pulsed with either E749-57 or E744-62 peptides. Treatment with dendritic cells pulsed with a ?short peptide resulted in the tumourgrowth inhibition, albeit weaker as compared to the immunisation with the longer peptide-containing DC. Our data demonstrate that cell-based vaccines can be designed to elicit immunity against MHC class I-deficient tumours.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

EB - Genetika a molekulární biologie

OECD FORD obor

—

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2010

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

International Journal of Oncology

ISSN

1019-6439

e-ISSN

—

Svazek periodika

36

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

GR - Řecká republika

Počet stran výsledku

7

Strana od-do

—

Kód UT WoS článku

000274718400003

EID výsledku v databázi Scopus

—